Herald Therapeutics, Inc. is a development stage drug development start up that has licensed IP from the University of Minnesota. It has completed Phase 1 and 2a clinical trial results that show good safety and early efficacy for a new therapeutic drug therapy for severely ill patients with ARDS, which is acute respiratory distress syndrome, which occurs from about 60 lung illnesses or conditions that result in severe inflamation and fluid build up in the patients lungs. COVID-19 patients contract ARDS in its most severe state.
We are seeking a CEO to replace me as one of the founders of the company who is presently in the CEO position. I will step back to the roll of General Counsel at the time we hire a new CEO. We are looking for an individual who has great skills in the area of (i) raising capital; (ii) managing clinical trial programs and preclinical development work; (iii) managing people (staff of likely under 15 and some consultants; (iv) good with budgeting and financial planning and income and balance sheets; and (v) has prior experience as a CEO or senior level executive in the pharmaceutical or bioligic industries. Prior experience is important to our hiring decision.
Send resumes to me at this site.
Drew S. Backstrand
CEO
Herald Therapeutics, Inc.